BeOne Medicines Ltd. ONC
1 target with a reported result
Releases of the last 3 yearsThe numbers ONC said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Operating income Fiscal 2026 |
Given $750.00M to $850.00M release May 6, 2026
Raised $1.00B to $1.10B release Aug 5, 2026
Raised $1.20B to $1.30B release Nov 5, 2026
|
– | Not reported yet | |
The company's wordsPrior FY 2026 Guidance Current FY 2026 Guidance1 … GAAP operating income2 $750 - $850 million release May 6, 2026 Prior FY 2026 Guidance Current FY 2026 Guidance1 … GAAP operating income2 $1.0B - $1.1B release Aug 5, 2026 Prior FY 2026 Guidance Current FY 2026 Guidance1 … GAAP operating income2 $1.2B - $1.3B release Nov 5, 2026 | ||||
| Revenue Fiscal 2026 |
Given $6.20B to $6.40B release Feb 26, 2026
Raised $6.30B to $6.50B release May 6, 2026
Raised $6.60B to $6.80B release Aug 5, 2026
Raised $6.90B to $7.00B release Nov 5, 2026
|
– | Not reported yet | |
The company's wordsFull year 2026 total revenue guidance of $6.2 billion to $6.4 billion release Feb 26, 2026 Prior FY 2026 Guidance Current FY 2026 Guidance1 … Total revenue $6.3 - $6.5 billion release May 6, 2026 Raised 2026 total revenue guidance to $6.6 to $6.8 billion; release Aug 5, 2026 Raised 2026 total revenue guidance to $6.9 to $7.0 billion; release Nov 5, 2026 | ||||
| Revenue Fiscal 2025 (ended Dec 31, 2025) |
Given $4.90B to $5.30B release Feb 27, 2025
Kept $4.90B to $5.30B release May 7, 2025
Raised $5.00B to $5.30B release Aug 6, 2025
Raised $5.10B to $5.30B release Nov 6, 2025
|
$5.34B 10-K filed 2026-02-26 |
Above the range | |
The company's wordsFull year 2025 revenue guidance of $4.9 billion to $5.3 billion, reaffirm anticipated positive GAAP operating income and cash flow generation from operations in 2025 SAN MATEO, Calif. – (BUSINESS WIRE) – BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; release Feb 27, 2025 BeiGene’s total revenue guidance for full year 2025 of $4.9 billion to $5.3 billion includes expectations for strong revenue growth driven by BRUKINSA’s U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. release May 7, 2025 Prior FY 2025 Guidance1 Current FY 2025 Guidance1 … Total Revenue $5.0 - $5.3B release Aug 6, 2025 Prior FY 2025 Guidance1 Current FY 2025 Guidance1 … Total Revenue $5.1 - $5.3B release Nov 6, 2025 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (18 releases since 2024-02-26), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ONC/export.csv") into a cell.